Exact(3)
Patients were allowed to continue stable oral corticosteroids (⩽10 mg/day prednisone or equivalent) and/or non-steroidal anti-inflammatory drugs.
Patients were requested to continue stable doses of baseline antidiabetes treatments (metformin, sulfonylureas, and/or insulin) and were asked not to change their diet and exercise habits during the study.
Patients were permitted to continue stable use of oral sustained-release theophylline (use of other methylxanthines was not permitted), inhaled corticosteroids, and oral or parenteral corticosteroids (prednisone ≤10 mg/day or 20 mg/every other day, or equivalent), except ≤6 hours before each visit.
Similar(55)
Patients with no local tumour benefit could continue stable maintenance doses of hormonal therapy and radiation therapy to distant, non-target metastases that developed during the study.
Similarly, Carrieri et al. [ 37] found a positive development of HRQL in patients switching to a non-PI-containing therapy, as compared to patients continuing stable PI-ART.
Patients could continue stable methotrexate, sulfasalazine, hydroxychloroquine, corticosteroids and non-steroidal anti-inflammatory drug treatment.
In addition, subjects could continue stable pharmacological treatment for coexisting disorders if we did not suspect treatment interfering with methylphenidate.
In one study [ 2], participants were allowed to continue a stable intake of cholinesterase inhibitors.
If already using non-steroidal anti-inflammatory drugs, participants will be permitted to continue their stable dose.
Patients receiving prescribed anti-inflammatory or pain-relieving medication will be permitted to continue a stable dose.
In both parts, patients were to continue their stable baseline dose of MTX through week 24, except when dosage adjustments were required due to MTX toxicity.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com